Zy Therapeutics

Zy TherapeuticsZy TherapeuticsZy Therapeutics

Zy Therapeutics

Zy TherapeuticsZy TherapeuticsZy Therapeutics
  • Home
  • About
  • The Problem
  • About BCDs
    • Sturge-Weber Syndrome
    • Tuberos Sclerosis
    • Neurocysticerosis
  • Our Solution
  • Who We Are
  • Corporate Communications
  • Contact Us
  • CTA
  • For Partners' Page
  • Publications
  • More
    • Home
    • About
    • The Problem
    • About BCDs
      • Sturge-Weber Syndrome
      • Tuberos Sclerosis
      • Neurocysticerosis
    • Our Solution
    • Who We Are
    • Corporate Communications
    • Contact Us
    • CTA
    • For Partners' Page
    • Publications
  • Home
  • About
  • The Problem
  • About BCDs
    • Sturge-Weber Syndrome
    • Tuberos Sclerosis
    • Neurocysticerosis
  • Our Solution
  • Who We Are
  • Corporate Communications
  • Contact Us
  • CTA
  • For Partners' Page
  • Publications

About Us

What We Do

  

Zy Therapeutics, LLC is a rare disease biotech developing the first therapy to directly target brain calcifications, an overlooked driver of seizures, cognitive decline, and disability in rare CNS disorders. Our work is guided by both professional experience and personal connections to the conditions we aim to treat. 


Zy represents a revolutionary step forward in the creation of lean biopharmaceuticals that develop life-saving medications in shorter amounts of time and at a fraction of traditional costs


By improving brain delivery of a proven safe molecule, we aim to deliver the first disease-modifying treatment for these devastating conditions. 


Our mission is simple: Transform brain calcification into a treatable target and bring hope to patients and families living with rare CNS disorders. 


Connect With Us

Zy Therapeutics

Copyright © 2025 Zy Therapeutics - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept